MedTrace Logo

Description of the Ability to Learn How to Handle Inhaler Devices in Asthma

NCT03175926 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2019-02-04

No results posted yet for this study

Summary

Asthma is a major public health problem. The main treatments against asthma are delivered to the lung through several dry-powder inhaler such as Turbuhaler ®, Diskus® and the new Ellipta® device. In real life, patient's ability to handle a device is not routinely assessed by their practitioner. We hypothesized that many asthmatics cannot properly prepare and prime their device, which may alter the positive effects observed in clinical trials.

Conditions

Interventions

DEVICE

placebo Diskus®

device will be given daily for one week, two puffs per day

DEVICE

placebo Ellipta®

device will be given daily for one week, one puff per day

DEVICE

Pulmicort® Turbuhaler®

device will be given daily for one week, two puffs per day

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Pierre Olivier GIRODET, MD · University Hospital, Bordeaux

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2018-09-01
Completion
2018-09-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03175926 on ClinicalTrials.gov